Who We Are

Dr. Emma Hapke, MD, FRCPC, is a psychiatrist, psychotherapist and psychedelic researcher. She started her career as an attending psychiatrist at CAMH in Toronto. Her specialty is women's mental health and the treatment of developmental trauma, sexual trauma and complex PTSD. Dr. Hapke is also a lecturer at the University of Toronto. She has extensive training in multiple types of psychotherapy and has worked clinically with ketamine-assisted psychotherapy. She also has a growing interest in psychosocial oncology. Dr. Hapke works with MAPS as the principal investigator for the Montreal site of a phase III study examining MDMA-assisted psychotherapy for PTSD and is MAPS-trained to deliver MDMA-assisted psychotherapy. In the spring of 2021, Dr. Hapke joined UHN as an attending psychiatrist and is the co-founder of the UHN Psychedelic Psychotherapy Research Group.

Dr. Daniel Rosenbaum, MD, FRCPC, is an attending psychiatrist at UHN as well as the Inner City Health Associates (ICHA) in Toronto. He is also a clinical lecturer in the Department of Psychiatry at the University of Toronto. He works on an Assertive Community Treatment Team, serving people with severe and persistent mental illnesses (SPMI), as well as the Palliative Education and Care for the Homeless (PEACH) team through ICHA. Dr. Rosenbaum is interested in psychosocial oncology and palliative care, especially end-of-life issues for marginalized populations. He is a certified CALM therapist (Managing Cancer and Living Meaningfully) and has received training in ketamine-assisted psychotherapy. He is a trainee in the fall 2021 cohort of the MAPS MDMA Therapy Training Program. He is also the co-founder of the Canadian Climate Psychiatry Alliance. Dr. Rosenbaum has published articles in peer-reviewed journals on psychedelic-assisted therapy in palliative and cancer care and on psychedelic microdosing. He is a co-founder and faculty member of the UHN Psychedelic Psychotherapy Research Group.

Dr. Yarissa Herman, CPsych, is a psychologist at the Centre for Addiction and Mental Health, where she is the head of a substance use Harm Reduction Program for individuals with severe and persistent mental illness. She has published in the area of psychosocial interventions for substance use and psychotic spectrum disorders. Dr. Herman has expertise in the area of program development, implementation and evaluation as well as quality improvement. She leads and evaluates large education initiatives and provides ongoing training and supervision in a number of therapeutic modalities. She is a co-investigator in a MAPS Canada research study exploring the use of psychedelics among individuals with mental health disorders, including severe and persistent mental illnesses. She has received training in ketamine-assisted psychotherapy and has completed the MAPS MDMA training program. She is a faculty member of the UHN Psychedelic Psychotherapy Research Group.

Dr. Susan Abbey, MD, FRCPC, is the Psychiatrist-in-Chief at UHN and a Professor in University of Toronto's Department of Psychiatry. A member of the Department of Psychiatry since 1991, she has received numerous academic awards and honours, including the Robin Hunter Award for Excellence in Postgraduate Psychiatric Education and the Prix d'Excellence from the Royal College of Physicians and Surgeons of Canada. She has been the President of the Canadian Psychiatric Association. Dr. Abbey's research and clinical interests relate to the psychiatric care of patients in medical and surgical settings, and the use of mindfulness-based stress reduction (MBSR) in the management of medical illness. She was an early adopter of Interpersonal Psychotherapy for Depression (IPT), and has taught IPT to international audiences. She has been teaching MSBR since 2000 and is part of a research group studying the role of mindfulness-based cognitive therapy (MBCT) in preventing depressive relapse following rTMS treatment. Dr. Abbey is delighted to champion the path forward for psychedelic-assisted psychotherapy as it potentially offers much-needed new treatment options for some of the most significant mental health challenges.